AcouSort places a modified AcouWash at Lund University to support cancer research

AcouSort has placed an AcouWash at Lund University. The system is modified to perform separation of circulating tumor cells (CTCs) from white blood cells. The modified AcouWash is similar to the system that was sold to Umeå University in 2020 and will be used in a clinical study comparing different methods for discovering CTCs in patient samples.

The AcouWash placed at Lund University has been modified to enable separation of circulating tumor cells (CTC) from white blood cells. The goal for Lund University’s research group is to use the modified AcouWash in a clinical study, benchmarking it against other CTC isolation methods, such as CELLSEARCH, which currently is the only method approved for clinical use.

– This strategic placement of the system is an important step towards our ambition of securing acoustofluidics in applications related to cancer detection and personalized therapeutics. Current methods are limited and can only find a fraction of the cancer cells, whereas our label-free acoustic method could be less limited and thus better at discovering more CTC types. This could mean that with AcouSort’s method, cancer can be detected at an earlier stage, says AcouSort’s CEO Torsten Freltoft.

Detection of circulating tumor cells in blood samples is a promising method for early cancer discovery. Lund University has previously used an acoustic research setup for their CTC research but will now have access to AcouWash to automate and increase the robustness of the process, allowing for a large scale clinical study. Lund University will also use the modified AcouWash to strengthen their collaboration with Umeå University and develop common protocols.

For further information on AcouSort, please contact:

Torsten Freltoft, CEO
Telephone: +45 2045 0854
E-mail: torsten.freltoft@acousort.com

About AcouSort

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify and stain cells, exosomes and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company’s Certified Adviser is Erik Penser Bank, 08-463 83 00,certifiedadviser@penser.se Erik Penser Bank AB (publ), Apelbergsgatan 27, Box 7405, 103 91 Stockholm.